ANDA 201528, held by Accord Hlthcare. Temozolomide.
As of Nov 16, 2026, ANDA 201528 (Temozolomide), held by Accord Hlthcare, was first approved by FDA on Feb 27, 2017, with 4 approved supplements and 0 published complete response letters.
Temozolomide is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. Anaplastic astrocytoma. Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. Treatment of adults with refractory anaplastic astrocytoma. 1.1 Newly Diagnosed Glioblastoma Temozolomide capsule is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2017 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Rx |
| Temozolomide20MG · capsule;oral | Temozolomide | Rx |
| Temozolomide100MG · capsule;oral | Temozolomide | Rx |
| Temozolomide140MG · capsule;oral | Temozolomide | Rx |
| Temozolomide180MG · capsule;oral | Temozolomide | Rx |
| Temozolomide250MG · capsule;oral | Temozolomide | Rx |
| May 15, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 13, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 27, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters